A Specialist Describes his experience with a hybrid choice concierge program from concierge choice physicians
Learn how the relationship has worked for his practice and his patients
for more than 10 years!
for more than 10 years!
|
|
Dr. Larry Good has been practicing gastroenterology since 1978. Dr. Good graduated Colgate University Magna Cum Laude in 1969 and received his M.D. with Alpha Omega Alpha status from the Medical University of South Carolina in Charleston, SC in 1973.
Dr. Good served a medical residency from 1973-76 and was Chief Medical Resident in 1976. He completed a fellowship in gastroenterology at the University of Pennsylvania from 1976-78.
Dr. Good has served as the Director of Liver Diseases at Nassau County Medical Center and was for many years Chief, Division of Gastroenterology, Department of Medicine at South Nassau Communities Hospital. He is an assistant clinical professor of medicine at SUNY Stony Brook and has given hundreds of lectures and authored numerous papers and abstracts.
Dr. Good has been Chief Medical Officer at Ritter Pharmaceuticals, where he expanded his research interest in the intestinal microbiome. His current clinical research involves the microbiome, inflammatory bowel disease, irritable bowel syndrome and orally administered gamma globulin for gastrointestinal disorders.
Dr. Good founded Good Pharmaceutical Development Co., LLC, in 2014, developing topical products for neuropathic pain. He was appointed editor of BMC Gastroenterology and continues to actively pursue clinical research.
Dr. Good served a medical residency from 1973-76 and was Chief Medical Resident in 1976. He completed a fellowship in gastroenterology at the University of Pennsylvania from 1976-78.
Dr. Good has served as the Director of Liver Diseases at Nassau County Medical Center and was for many years Chief, Division of Gastroenterology, Department of Medicine at South Nassau Communities Hospital. He is an assistant clinical professor of medicine at SUNY Stony Brook and has given hundreds of lectures and authored numerous papers and abstracts.
Dr. Good has been Chief Medical Officer at Ritter Pharmaceuticals, where he expanded his research interest in the intestinal microbiome. His current clinical research involves the microbiome, inflammatory bowel disease, irritable bowel syndrome and orally administered gamma globulin for gastrointestinal disorders.
Dr. Good founded Good Pharmaceutical Development Co., LLC, in 2014, developing topical products for neuropathic pain. He was appointed editor of BMC Gastroenterology and continues to actively pursue clinical research.
